cis-Ergoline | 478-88-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: cis-Ergoline
• 英文别名: 4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline
• CAS: 478-88-6
• 化学式: C₁₄H₁₆N₂
• 分子量: 212.29
• InChiKey: RHGUXDUPXYFCTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• Improvements in or relating to ergoline derivatives
  申请人：ELI LILLY AND COMPANY

  公开号：EP0375297A2

  公开（公告）日：1990-06-27

  (8β)-N-heteroalkyl-1- alkyl-6-(substituted) ergoline-8-carboxamides of the formula wherein: R¹ is C₁-C₄ alkyl; R² is allyl or C₁-C₄ straight chain alkyl; R³ is hydrogen or C₁-C₄ straight chain alkyl; R⁴ is pyridinyl or imidazolyl; alk is a divalent organic radical derived from a straight or branched C₁-C₅ alkane; or a pharmaceutically acceptable acid addition salt thereof. The compounds are useful for blocking 5HT₂ receptors in mammals having an excess of serotonin centrally or peripherally

  (8β)-N-杂烷基-1-烷基-6-（取代的）麦角啉-8-甲酰胺，其式为 其中 R¹ 是 C₁-C₄ 烷基； R² 是烯丙基或 C₁-C₄ 直链烷基； R³ 是氢或 C₁-C₄ 直链烷基； R⁴ 是吡啶基或咪唑基； 烷基是二价有机基，来源于直链或支链 C₁-C₅ 烷烃；或 其药学上可接受的酸加成盐。 这些化合物可用于阻断中枢或外周羟色胺过量的哺乳动物的 5HT₂ 受体。
• DIAGNOSTIC COMPOUNDS COMPRISING A SCAFFOLD COUPLED TO A SIGNAL ENTITY FOR MEDICAL IMAGING DIAGNOSTIC
  申请人：COROT Claire

  公开号：US20070098631A2

  公开（公告）日：2007-05-03

  The present invention concerns a diagnostic compound of formula (SCAFFOLD) n1 -(LINKER) n3 -(SIGNAL) n2 -(M),  (E) wherein SCAFFOLD is chosen in table 2: namely Biphenyl; Arylpiperidine; Arylpiperazine; 1,4 dyhydropyridine; Dihydropyrimidone; 1,4 benzodiazepine-2-one; 1,5 benzodiazepine-2-one; 1,4-benzodiazepine-2,5 diones; pyrrolo2,1-c 1,4 benzodiazepines 5,11 diones; 1,4 benzothiazepine-5-ones; 5,11-dihydro-benzo pyrido 3,2b 1,4 diazepine-6-ones Benzopyrane; Chromone; Benzopyranone; Coumarine, pyranocoumarine Benzopiperazinones; Quinazolinone; Quinazolindione; Quinoxalinone Imidazoquinoxaline; indole; Benzimidazole Benzofurane Benzothiophene; SIGNAL is a signal entity for medical imaging diagnostic, and pharmaceutically acceptable salts thereof.
• ANTIPROLACTINIC VETERINARY COMPOSITION FOR RUMINANTS
  申请人：LAGARDE Anouck

  公开号：US20110245261A1

  公开（公告）日：2011-10-06

  This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly useful for promoting a substantial reduction of lactation, mammary involution, and for treating and/or intra-mammary diseases or infections of ruminants.
• VETERINARY ANTIPROLACTINIC COMPOSITION FOR RUMINANTS
  申请人：CEVA SANTE ANIMALE

  公开号：US20130203762A1

  公开（公告）日：2013-08-08

  This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly useful for reducing udder engorgement and/or the reduction of pain after drying off and/or of increasing welfare, and/or of reducing milk leakage in ruminants as well as for preventing new mammary microbial infections, secondary infection, or co-infections in ruminants and mastitis.
• VETERINARY ANTI-PROLACTIN COMPOSITION FOR RUMINANTS
  申请人：Isaka Naomi

  公开号：US20140024670A1

  公开（公告）日：2014-01-23

  The present invention relates to a veterinary anti-prolactin composition to be administered to ruminants. Said composition includes at least one anti-prolactin compound which is an agonist for dopamine receptors and which is particularly useful for preventing and/or reducing the harmful effects in ruminants linked to use for a shortened dry period. Said composition is particularly useful for preventing and/or reducing metabolic diseases and/or reproductive disorders when lactation is resumed. The use of the veterinary anti-prolactin composition according to the invention does not adversely affect the milk-producing ability and/or the milk quality of the treated ruminants